Building a true strategy about your pharmaceutical drugability
Years of experience
Clients
Studied molecules
Clarified strategies in terms of scope and prioritisation between studies
Shortened timelines for selecting higher value drug candidates
Lower risk in early development programs and optimisation of R&D costs
Higher project team autonomy in regulatory preclinical and clinical development
Enhanced chances for a much higher project valorisation
Latest news
2024 AFSSI Connexions
Back to the images of the 2024 AFSSI Connexions in Montpellier (2nd and 3rd of July)... Like last year, this 11th edition took place in the old medicine faculty of Montpellier for 48 hours of...
more news >